>>LGND is preparing a new cheat sheet, but the one put out on the fall of 1996 lists the following numbers for new patients in the US for indications targreted by Targretin and Panretin.
For Targretin they show 39,750 cases of head & neck, 22,200 Kaposi sarcoma, 169,900 lung cancer, 26,600 ovarian cancer, 244,000 prostate cancer, 28,800 renal cell cancer, and 6,000 skin lymphomas.
For Panretin they list head & neck, KS, ovarian, prostate, and renal cancers. In addition they show 1.2 million HIV, 2,500 APL, 12,500 multiple myeloma, and 50,900 non-Hodgkin lymphoma.<<
Thanks Henry. Please let me know when the new cheat sheet comes out. Back in June or July, LGND announced it had given up on Panretin indications for renal cancer as well as multiple myeloma and non-Hodgins lymphoma. |
